

Case Report

IMPETIGO HERPETIFORMIS IN A 36 WEEK PREGNANT WOMAN

Nurettin Aka / Zeynep Tuzcular Vural / Kemal Kuşçu / Eşref Yazıcıoğlu

M.D., Department of Gynecology and Obstetrics, Haydarpaşa Numune State Hospital, Istanbul, Turkey.

ABSTRACT

A case of impetigo herpetiformis seen in a 36 week pregnant woman is presented and relevant literature is reviewed.

Key Words: Impetigo herpetiformis, Pregnancy

INTRODUCTION

Impetigo Herpetiformis (IH) is a dermatologic disease consisting of pustules on an erythematous base covering large areas of skin. While some researchers accept IH as a type of pustular psoriasis, others accept IH to be solely a pregnancy-related disease (1,2). IH was first described by Von Hebra in 1872. The disease is seen mainly in the third trimester of pregnancy, but there are rare cases appearing in the first and second trimesters as well (3,4). There is resolution of the disease between pregnancies, but recurrences with subsequent pregnancies may be expected (5). Hypocalcemia and hypoparathyroidism are usually present (4).

Our aim in this paper is to present a case of impetigo herpetiformis seen in a 36 week pregnant woman and to scrutinize relevant literature.

CASE REPORT

A 36 week pregnant 32 year-old white woman (gravida 5, para 2, abortion 2) presented with pustules on an erythematous base. The gynecologic history of the patient was quite normal. Her history revealed nothing but a thyroid operation 12 years previously.

In her physical examination her blood pressure was measured to be 120/80 mmHg, pulse rate 105 per min, temperature 37°C. There were pustules on an

erythematous base on both deltoids, external earways, on her nose, neck, abdomen, groin and legs (Fig. 1). The mucous membranes were not involved. The thyroid was symmetrically large and tender with palpation. Chvostek and Trousseau signs were positive.

In obstetrical examination the collum was dilated 3 cm with 30-40% effacement. The size of the uterus corresponded to 35-36 weeks of pregnancy. The pouch was present and fetal cardiac activity was positive. The patient had infrequent contractions.

In obstetrical ultrasonographic examination the BPD and FL corresponded to 36 weeks of pregnancy. The placenta was located posteriorly with thickness of 7 cm (placental edema). In Doppler evaluation of the umbilical artery the A/B proportion was within the normal range (2.3).

Laboratory investigations showed an elevated white blood count (14,300 WBC/mm³) and erythrocyte sedimentation rate (78/90 mm in 30 minutes and 1 hour). Serum calcium was low (3.2 mg/dl) and phosphorus elevated (6.1 mg/dl). The total protein and albumin levels were also low (5.9 g/dl and 3.2 g/dl, consequently). Hepatic and renal function tests were slightly elevated. The serum triglycerid and alkaline phosphatase levels were markedly high (400 mg/dl and 498 IU/L, consequently). Thyroid function tests and other laboratory investigations were within the normal range. Electrocardiogram revealed QT lengthening.

The throat culture revealed normal flora of the throat and cultures from the pustules were sterile.

The histo-pathologic examination of punch biopsies of the pustules showed spongiiform pustules filled with eosinophils and neutrophils located immediately under the parakeratotic stratum corneum. The dermis showed perivascular mononuclear cell infiltration.

Ülseratif Kolit Tedavisinde Etkili Remisyon **KALICI KORUMA**

"REMİSYONU ELDEN BIRAKMAYIN"

**Dipentum**[®]
(olsalazin)

Dipentum® 250 mg kapsül FORMULÜ Her kapsülde 250 mg olsalazin sodium bulunur. ENDİKASYONLARI Akut ülseratif kolit tedavisinde özellikle sulfasalazine karşı intolerans ve/ya ağır duvarlık gönen hastalarda kullanılır. KONTRENDİKASYONLARI Nisbolarına göre duvarlı alan hastalarda kontrendikedir. UYARILAR ÖNLEMLER Çocuklar, Gebeler ve Emzirenler İçin Özel Uyarılar: Denev hayvanları üzerinde yapılan araştırmalarda fetus üzerinde herhangi bir zarar etkisi saptanmamıştır. İnsanlarda benzer araştırmalar yapılmamıştır. Gebelikte kullanılması gerekli görüldüğü takdirde ilaçtan beklenen yarar ve fetus üzerine muhtemel zarar pozisyonuna alınmalıdır. Olsalazinin sütte geçip geçmediği bilinmemektedir. Pediatride etki ve güvenliği henüz yeterince araştırılmamıştır. YAN ETKİLER ADVERB ETKİLER Klinik araştırmalarda en sık karşılaşılan yan etkiler şunlardır: Diareye, vücut ağrısı, baş ağrısı, karın ağrısı, bulantı, mide rahatsızlığı hissi, deri döküntüleri ve eklem ağrıları. Diareye bazı hastalarda tedavinin kesilmesinin yeterli olduğu BELİRSİZLİKLER BİR ETKİLİ KORULUK GÜNÜNE DOKTORİNUZA BAŞVURUNUZ İLAÇ ETKİLEŞİMLERİ VE DİĞER ETKİLEŞİMLER Olsalazin sartan ile birlikte kullanıldığında hipertansiyonun azalmasıyla ilgili bulguların ortaya çıkmasıyla ilişkilendirilmiştir. KULLANIM ŞEKLİ VE HUZULU Bu amaçla her hafta alınmalıdır. Etkileri Akut ülseratif kolit tedavisinde günlük doz 8 kapsüldür. Bu doz 4 veya 3'e bölünebilir. En sık günlük doz 3 gramdır. Ancak bu kezde verilen doz 1 gramı 4 kapsül sayılmaktadır. Yan etkilerin ortası etkisine ulaşmış azalmak için tedavinin dozuyla hastanın uyumlanabilmesi için günde 2 kapsül idame tedavisi 12 saatte bir 2 kapsül günde toplam 4 kapsül uygulanır. Kapsüller yemeklerin hemen ardından alınmalı ve uygulama zamanını dikkat edilmelidir. Remisyondaki hastaların idame tedavisi: İlk 3 hafta günde üç kez 3 gramdır. 4 kapsül. Bu bölünerek alınmalıdır. Diareye gelişen hastalarda günlük toplam dozun ilk günlerde daha fazla bölünerek alınması 3-4 saatte bir gibi gerekebilir. Yaşlılara da erişkin doz uygulanır. DOZ AŞIMI HAZINDE ALINACAK ÖNLEMLER Olsalazin özel bir antidot yoktur. Hasta yakasının semptomları ve gerekirse semptomatik tedavi uygulanmalıdır. SAKLANMA KOŞULLARI Her kapsülün kaplı olduğu kutu bir seride 120 kapsül arasında saklanmalıdır. Raf ömrü 5 yıldır. Doktorla danışmadan kullanılmamalıdır. Çocukların ulaşamayacakları yerlerde ve ısıdan korunmuş şekilde saklanmalıdır. TİCARİ TAKDİM ŞEKLİ VE AMBALAJ MİKTEVANLI Her kapsülde 250 mg olsalazin sodium içerir. 100 kapsülde ambalajlanmıştır.



Pharmacia
& Upjohn

Eczacıbaşı İlaç

Diğer ilaçları için karışık amaçlı ilaçlar için
Eczacıbaşı İlaç Pazarlama
Buyukdere Cad. 185 80710 Levent-İstanbul

Eczacıbaşı

Postmenopozal osteoporozda kırıkların önlenmesini sağlayın.¹

F
I
T

FRACTURE
INTERVENTION
TRIAL

F
O
S
I
T

FOSAMAX
INTERNATIONAL
TRIALS

HIZLI

Vertebra dışı kırık insidansını bir yıl içinde **%47** oranında azaltmıştır (p=0,021).²

ERKEN

İlk kırık insidansını **%44** oranında azaltmıştır (p=0,001).²

TÜM BÖLGELERDE

Kalça kırığı oluşma insidansını **%51** oranında ve diğer kritik osteoporoz bölgelerinde kırık insidansını önemli derecede azaltmıştır (p=0,047).¹

REFERANSLAR

1. Black DM et al for the Fracture Intervention Trial Research Group.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.

Lancet 1996; 348: 1535-1541

2. Data on file, MSD Türkiye.

GÜNDE BİR KEZ 10 MG FOSAMAX OLARAK REÇETELEYİNİZ.

Kontrendikasyonlar, uyarılar, önlemler ve yan etkiler ile ilgili detaylı bilgiler için lütfen prospektüse başvurunuz.



MERCK SHARP & DOHME

† MERCK & Co., Inc., Whitehouse Station N.J., USA'nın tescilli markasıdır.

Copyright © Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., 1998.

Tüm hakları saklıdır. 12-99-FSM-98-MEA-2042-J(TR)

F
O
S
A
M
A
X[®] †

alendronat
sodyum

GAMMA KNİFE

(Türkiye ve çevre ülkelerde ilk ve tek)
Beyin Patolojilerinde
cerrahi müdahaleye gerek kalmaksızın
tedavi olanağı

Radyasyon Onkolojisi

Saturn 42 Lineer Akseleratör
Target Doz Planlama Üniti
Nuclital Simulator

Nükleer Tıp


Camstar X-CT
Camstar X-RT
Optima
Genie Work Stations

Radyodiagnostik

Magnetic Rezonans
Helical Bilgisayarlı
Tomografi
DSA Angiography
Preferic Angiography
Mammografi
Floroscopy
Konvansiyonel X-Ray
Mobile X-Ray
Ultrasonografi
Doppler Ultrasonografi
Advantage Windows
(Görüntü Değerlendirme
Sistemleri)



Networking System

Ülkemizin en kapsamlı ve modern Teşhis/Tedavi Merkezi




**GE Medical Systems
&
MARMARA
ÜNİVERSİTESİ**

İŞBİRLİĞİ



**Marmara Üniversitesi Tıp Fakültesi Hastanesi 1. ve 2. bodrum katlar
Telefon: (0216) 327 69 50 (4 Hat)**



*Bir kitabın yaşadığı bütün aşamaları
beraber gerçekleştirebiliriz...*

Size daktilo sayfalarıyla gelmeniz yeterli.

Kitap ve süreli yayınlarda

Kurtiş Matbaacılık.




Fig.1:
Impetigo
herpetiformis
before
treatment




Fig.2:
Impetigo
herpetiformis
after
treatment

The patient was hospitalized, and vital functions were monitored. Calcium gluconate was administered intravenously and local applications of eau de goulard and corticosteroids were applied after consultations from the Internal Medicine and Dermatology Departments. Prophylactic antibiotics were administered. After 3 days of intravenous calcium administration, the blood calcium value was elevated to 5.1 mg/dl. Urine

output was 900 cc in 24 hours. The patient gave birth to a 2500 g baby girl with Apgar score 8/10 on the same day with normal delivery after induction of labour. The neonate was evaluated to be normal after physical examination and routine laboratory studies. After intravenous infusion of calcium for 4 days postpartum, calcium 1000 mg tab. and Rocaltrol 0.25 mg cap. per oral 4 times a day was administered.

After delivery, eruptions cleared rapidly, and after desquamation the skin appeared normal on the seventh day of delivery (Fig. 2). Recurrences of IH are reported after oral contraceptive use (6,7), therefore an intrauterine contraceptive device was applied on the 9th day after delivery.

DISCUSSION

It is very difficult to understand the etiology of this disease which presents with white sterile pustules appearing on an erythematous base, because it is seen so rarely. Researchers are investigating the relation of IH with estrogen-progesterone, Vitamin D metabolism, autoimmunity and genetic factors (4,6,8,9).

In a paper published in England in 1989, cases of IH seen in two sisters during their first pregnancy have been reported. The fact that they had identical HLA antigens (A11, AW24, BW44, BW54, DR64) suggests autoimmunity in the etiology (8).

In 1982 Oumeish et al (7) in 1988 Winzer and Wolff (6), reported cases of IH both during pregnancy and oral contraceptive use. This fact shows that there might be a relation between IH and estrogen-progesterone use.

A case of IH in a patient with congenital rickets and recessive ichthyosis with IH seen in the second trimester of pregnancy presenting after hypocalcemia due to termination of drug therapy (4), has been reported. In our case, the parathormone and thyroid hormone values were within the normal range, but hypocalcemia was present together with history of a thyroid operation. While there are reports of cases persisting weeks or even months after delivery (10), there are also cases of immediate resolution with delivery, as was the case with our patient.

The complex of symptoms has an unfortunate name because it is neither related to bacterial infection (impetigo), nor herpes virus infection.

Impetigo herpetiformis is a rare, severe dermatologic disorder which occurs predominantly in the last trimester of pregnancy. About 355 cases have been reported to date in Europe and the United States (2,9,11-15). Impetigo herpetiformis tends to worsen as the pregnancy progresses and is associated with severe maternal and fetal complications. The reason for increased fetal mortality is not clear: it may be related to disturbances of maternal circulation or to placental insufficiency (14). Prompt diagnosis with

appropriate treatment can result in a quick resolution, as in our case. It should always be kept in mind that misdiagnosis or delay in treatment may result in severe maternal and fetal complications.

REFERENCES

1. Arnold HL, Odom RB, James WD. *Andrews' diseases of the skin. Clinical dermatology. 8th edition. Philadelphia, WB Saunders, 1990:551.*
2. Kuijpers AL, Schaalkwijk J, Rulo HF, Peperkamp JJ, van de Kerkhof PC, de Jong EM. *Extremely low levels of epidermal skin-derived antileucoprotease/elafin in a patient with impetigo herpetiformis. Br J Dermatol 1997;137:123-129.*
3. Sasseville D, Wilkinson RD, Schnader SY. *Dermatoses of pregnancy. Int J Dermatol 1981;20:223-241.*
4. Holm AL, Goldsmith LA. *Impetigo herpetiformis associated with hypocalcemia of congenital rickets. Arch Dermatol 1991; 127:91-95.*
5. Beveridge GW, Harkness RA, Livingstone JR. *Impetigo herpetiformis in two successive pregnancies. Br J Dermatol 1966;78:106-112.*
6. Winzer M, Wolff HH. *Impetigo herpetiformis. Hautarzt 1988;39:110-113.*
7. Oumeis OY, Farraj SE, Bataineh AS. *Some aspects of impetigo herpetiformis. Arch Dermatol 1982;118:103-105.*
8. Tada J, Fukuskiro S. *Two sisters with impetigo herpetiformis. Clin Exp Dermatol 1989;14:82-84.*
9. Vicdan K, Gökay Z, Var T, Danişman N, Gökmen O. *Twin sisters with impetigo herpetiformis. Eur J Obstet Gynecol Reprod Biol 1995;63:195-196.*
10. Oosterling RJ, Nobrega RE, Du-Boeuff JA, Van-Der-Meer JB. *Impetigo herpetiformis or generalized pustular psoriasis? Arch Dermatol 1978;114:1527-1529.*
11. Gleicher N. *Principles of medical therapy in pregnancy. New York, Plenum Medical Book Co, 1985:1152-1153.*
12. Ott F, Krakowski A, Tur E, et al. *Impetigo herpetiformis with lowered serum level of vitamin D and its diminished intestinal absorption. Dermatologica 1982;164:360-365.*
13. Trevisan G, Kokelj F. *Impetigo herpetiformis and RhE isoimmunization: a case report. Cutis 1996;58:87-89.*
14. Wolf Y, Groutz A, Walman I, Luxman D, David MP. *Impetigo herpetiformis during pregnancy: case report and review of the literature. Acta Obstet Gynecol Scand 1995;74:229-232.*
15. Errikson CV, Matus NR. *Skin disorders of pregnancy. Am Fam Physician 1994;49:605-610.*